| Dutch tariff for the five-level version of EQ-5D MM Versteegh, KM Vermeulen, SMAA Evers, GA De Wit, R Prenger, ... Value in health 19 (4), 343-352, 2016 | 962 | 2016 |
| Time trade-off: one methodology, different methods AE Attema, Y Edelaar-Peeters, MM Versteegh, EA Stolk The European Journal of Health Economics 14, 53-64, 2013 | 168 | 2013 |
| Patient and general public preferences for health states: a call to reconsider current guidelines MM Versteegh, WBF Brouwer Social Science & Medicine 165, 66-74, 2016 | 159 | 2016 |
| Introducing the composite time trade-off: a test of feasibility and face validity BMF Janssen, M Oppe, MM Versteegh, EA Stolk The European Journal of Health Economics 14, 5-13, 2013 | 147 | 2013 |
| When is it too expensive? Cost-effectiveness thresholds and health care decision-making W Brouwer, P van Baal, J van Exel, M Versteegh The European Journal of Health Economics 20, 175-180, 2019 | 143 | 2019 |
| Condition-specific preference-based measures: benefit or burden? MM Versteegh, A Leunis, CA Uyl-de Groot, EA Stolk Value in Health 15 (3), 504-513, 2012 | 121 | 2012 |
| From good to better: new Dutch guidelines for economic evaluations in healthcare M Versteegh, S Knies, W Brouwer Pharmacoeconomics 34, 1071-1074, 2016 | 110 | 2016 |
| Severity-adjusted probability of being cost effective MM Versteegh, IC Ramos, NC Buyukkaramikli, A Ansaripour, ... Pharmacoeconomics 37, 1155-1163, 2019 | 84 | 2019 |
| Mapping onto Eq-5 D for patients in poor health MM Versteegh, D Rowen, JE Brazier, EA Stolk Health and Quality of life Outcomes 8, 1-13, 2010 | 73 | 2010 |
| A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending P van Baal, M Perry‐Duxbury, P Bakx, M Versteegh, E Van Doorslaer, ... Health Economics 28 (1), 87-100, 2019 | 66 | 2019 |
| Mapping Qlq-C30, Haq, and Msis-29 on Eq-5d MM Versteegh, A Leunis, JJ Luime, M Boggild, CA Uyl-de Groot, EA Stolk Medical Decision Making 32 (4), 554-568, 2012 | 65 | 2012 |
| Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma S de Groot, WK Redekop, MM Versteegh, S Sleijfer, E Oosterwijk, ... Quality of Life Research 27, 115-124, 2018 | 63 | 2018 |
| Lead time TTO: leading to better health state valuations? AE Attema, MM Versteegh, M Oppe, WBF Brouwer, EA Stolk Health economics 22 (4), 376-392, 2013 | 51 | 2013 |
| The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health … FCW Van Krugten, JJV Busschbach, MM Versteegh, ... Quality of Life Research, 1-11, 2021 | 49 | 2021 |
| Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the … IC Ramos, MM Versteegh, RA de Boer, JMA Koenders, GCM Linssen, ... Value in Health 20 (10), 1260-1269, 2017 | 49 | 2017 |
| Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-AD) C Koedoot, M Versteegh, JS Yaruss Journal of Fluency Disorders 36 (3), 222-230, 2011 | 47 | 2011 |
| Are health state valuations from the general public biased? A test of health state reference dependency using self‐assessed health and an efficient discrete choice experiment MF Jonker, AE Attema, B Donkers, EA Stolk, MM Versteegh Health economics 26 (12), 1534-1547, 2017 | 43 | 2017 |
| Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options R Koleva-Kolarova, J Buchanan, H Vellekoop, S Huygens, M Versteegh, ... Applied Health Economics and Health Policy 20 (4), 501-524, 2022 | 42 | 2022 |
| Quality of life among people living with HIV in England and the Netherlands: a population-based study S Popping, M Kall, BE Nichols, E Stempher, L Versteegh, ... The Lancet Regional Health–Europe 8, 2021 | 42 | 2021 |
| Guidance for the harmonisation and improvement of economic evaluations of personalised medicine H Vellekoop, S Huygens, M Versteegh, L Szilberhorn, T Zelei, B Nagy, ... Pharmacoeconomics 39 (7), 771-788, 2021 | 40 | 2021 |
